HYTN Awarded Drug Establishment License from Health Canada, Expanding GMP Capabilities
VANCOUVER, British Columbia, June 27, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has been granted a Drug Establishment License (DEL) by Health Canada. This license allows HYTN to engage in the GMP fabrication, packaging, and labeling of non-sterile pharmaceuticals containing both cannabis and psilocybin, significantly enhancing the Company’s capabilities and expanding its market reach. With this license, HYTN is now positioned to manufacture and export these pharmaceutical products into regulated global markets, further solidifying its status as one of the very few companies in the sector with these capabilities.
Related news for (HYTNF)
- HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities
- HYTN Welcomes U.S. Recommendation to Reclassify Cannabis, Foresees Growth
- HYTN Innovates GMP Stability Programs, Sets Industry Benchmark
- HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities